Last reviewed · How we verify

Saphris — Competitive Intelligence Brief

Saphris (ASENAPINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic [EPC]. Area: Neuroscience.

marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2C Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Saphris (ASENAPINE) — Hisamitsu. Saphris works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2C.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Saphris TARGET ASENAPINE Hisamitsu marketed Atypical Antipsychotic [EPC] 5-hydroxytryptamine receptor 2C 2009-01-01
Belviq LORCASERIN Eisai marketed Serotonin-2c Receptor Agonist 5-hydroxytryptamine receptor 2C 2012-01-01
Remeron mirtazapine Generic (originally Organon/MSD) marketed NaSSA (Noradrenergic and specific serotonergic antidepressant) 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1996-06-14
Zerdol SERTINDOLE H. Lundbeck A/S marketed sertindole 5-hydroxytryptamine receptor 2C 1996-01-01
Effexor venlafaxine Generic (originally Wyeth/Pfizer) marketed SNRI (Serotonin-norepinephrine reuptake inhibitor) 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C 1993-12-28
Amoxil amoxicillin Generic (originally Beecham/GSK) marketed Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Amoxicilli Amoxicilli Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. marketed 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Atypical Antipsychotic [EPC] class)

  1. · 2 drugs in this class
  2. AbbVie · 1 drug in this class
  3. Alkermes Inc · 1 drug in this class
  4. Eli Lilly · 1 drug in this class
  5. Hisamitsu · 1 drug in this class
  6. Intra-Cellular · 1 drug in this class
  7. Jazz Pharmaceuticals · 1 drug in this class
  8. Johnson & Johnson (Janssen) · 1 drug in this class
  9. Otsuka · 1 drug in this class
  10. Vanda Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saphris — Competitive Intelligence Brief. https://druglandscape.com/ci/asenapine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: